Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + everolimus
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trametinib + everolimus is a combination of two targeted small molecule inhibitors used in oncology clinical trials, particularly for the treatment of recurrent or advanced solid tumors such as gliomas and pancreatic cancer. Trametinib is a selective inhibitor of MEK1 and MEK2, components of the MAPK/ERK pathway, thereby disrupting tumor cell proliferation and survival. Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), blocking a separate signaling pathway involved in cell growth, proliferation, and survival. The rationale for combining these agents is to simultaneously inhibit two critical pathways that contribute to tumor progression and resistance mechanisms. This combination has been studied in phase I/II trials for pediatric gliomas and advanced solid tumors but has shown significant toxicity at higher doses[1][2]. Trametinib is developed by Novartis (as Mekinist), while everolimus (marketed as Afinitor) was also developed by Novartis[4][7].
- Brand names
- Certican
- Other names
- trametinib + everolimus
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on trametinib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + everolimus.